Objectives: Use of prescription opioids for chronic pain is increasing, as is abuse of these medications, though the nature of the link between these trends is unclear. These increases may be most marked in patients with mental health (MH) and substance use disorders (SUDs). We analyzed trends between 2000 and 2005 in opioid prescribing among individuals with noncancer pain conditions (NCPC), with and without MH and SUDs.
A pproximately 20% of the US population is significantly affected by pain lasting at least 6 months, 1,2 most commonly back pain, joint pain, and headache. [3] [4] [5] [6] [7] Individuals with noncancer pain conditions (NCPC) now commonly receive opioids as treatment for their NCPC. [8] [9] [10] This increased use is controversial with some believing that increased use of opioids for NCPC is a sign of better pain treatment, 11 whereas others warn that we do not have enough evidence of the ''safety and effectiveness of longterm opioid therapy'' in NCPC to justify its use. 12 Furthermore, there are concerns about ''iatrogenic opioid addiction,'' [13] [14] [15] [16] [17] [18] [19] [20] [21] opioid-induced hyperalgesia, 22 and opioidinduced decreases in quality of life. 23 It is likely that increased use of opioids both improves pain control and increases risk of misuse and addiction. Reflecting the key issue of balancing the benefits and risks, the Food and Drug Administration recently indicated that manufacturers of certain opioid drug products will be required to have a risk evaluation and mitigation strategy to ''ensure that the benefits of the drugs continue to outweigh the risks.'' 24 The clinical epidemiology of opioid use for NCPC is not well characterized, particularly in different subgroups. The comorbidity of NCPC with mental health (MH) disorders, such as depression or anxiety, is well established, [25] [26] [27] although little is known about the relationship between NCPC and substance use disorders (SUDs), such as alcohol or drug dependence. There has been debate about whether these NCPC precede or follow these MH disorders, but the best evidence suggests that both pathways are important. Several factors make the subgroup of NCPC patients with MH and SUDs particularly important to study. As patients with MH and SUDs have often been excluded from randomized opioid trials, we know less about the benefits of NCPC treatment with opioids in this group. 28 Furthermore, MH and SUD disorders may be risk factors for abuse of prescribed opioids. 6, 9, 14, 18, 19 Thus, individuals with MH and SUDs comprise the population in which the benefits of opioids are least established and the vulnerability to opioid addiction is highest. Studies from pain clinics and population surveys suggest that NCPC patients with MH and SUDs are more likely to receive opioids for NCPC 18, [29] [30] [31] [32] than NCPC patients without MH or SUDs, but the number of opioid users in these studies has been small, and details of opioid use are lacking.
Our objective was to analyze trends in opioid prescribing among individuals with NCPC with and without MH and SUDs, focusing on years 2000 and 2005. We used longitudinal administrative data from 2 dissimilar populations: a national, commercially insured population and Arkansas Medicaid to demonstrate the range of current trends. The use of administrative data has several advantages for this type of analysis, when compared with studies from pain clinics or community surveys. First, administrative data offer much larger samples, allowing extensive subgroup analysis. Second, samples from entire health plans are more representative than samples from primary or specialty clinical settings. Third, administrative pharmacy records offer detailed information on type of opioid, dose, and days supplied. Fourth, they do not suffer from recall bias, as might occur with surveys.
We focused on years 2000 and 2005, as we have previously shown that rates of increase were linear between those years, 33, 34 and investigated (1) rates of any prescription opioid use among individuals with NCPC and either MH or SUDs, (2) rates of use of prescription opioids for more than 90 days in the past year, (3) mean days supply of prescription opioids among those prescribed any opioids, (4) mean daily opioid dose in morphine equivalents, and (5) the percentage of the total opioid dose that was Schedule II opioids. These years are of particular interest, because in 2000 the Joint Commission on Accreditation of Healthcare Organizations initiated its ''Pain as the fifth vital sign'' campaign to promote appropriate pain treatment. 35 
MATERIALS AND METHODS

Study Populations Arkansas Medicaid
Arkansas is one of the poorest states with 26% of the Arkansas population qualifying for Medicaid benefits in 2005. 36 The 2005 total expenditures for the program were $3.0 billion dollars or $4368 per recipient. Arkansas Medicaid serves a disadvantaged and vulnerable population situated in the geographic region with the highest opioid use in the country. 30 Arkansas Medicaid covers all federally mandated services and nearly all federal optional services, including prescription drug, ambulatory surgical center services, and 44 other optional services. Most Arkansas Medicaid enrollees participate in the primary care physician program where recipients use a primary care provider to coordinate care. The Arkansas Medicaid program imposes some benefit limitations: 12 physician, clinic, and outpatient visits per year, six prescriptions per month, maximum of 24 inpatient days per year, and some coinsurance and copayments for prescription drugs and other services depending on eligibility type. Analyses of Medicaid claims indicate that Medicaid data are generally valid and suitable for epidemiologic uses. 37 
HealthCore
The HealthCore Integrated Research Database contains medical and pharmacy administrative claims and health plan eligibility data from 5 commercial health plans representing the West, Mid-west, and South-east regions. Data came from health plan members who were fully insured through several commercial insurance products, including health maintenance organizations, preferred provider organizations, and point of service providers. Health plan members all had full medical and pharmacy coverage with a range of co-pay and deductibles. Claims submitted with partial or complete subscriber liability (due to co-pay or deductible requirements) are captured.
Study Sample
The study sample consisted of enrollees in the 2 health plans in 2000 and 2005 who met the following 2 criteria. Inclusion criteria: (1) one or more recorded NCPC diagnoses based on ICD codes for back pain, neck pain, arthritis/joint pain, headache/migraine, and HIV/AIDS. We could not verify that these conditions were chronic or that these were the conditions for which opioids were prescribed, but chronic forms of these conditions are the most common indication for long-term opioid use in a general medical population, (2) age 18 or older, and (3) enrolled and eligible for benefits for at least 9 months in 2000 or 2005. Exclusion criteria: (1) cancer diagnosis at any time in 2000-2005 other than nonmelanoma skin cancer, (2) resident of nursing home, or (3) receiving hospice benefits. These criteria allow us to focus on outpatient enrollees likely receiving opioids for the treatment of NCPC.
MH and SUDs
Using ICD-9-CM codes, we created a dichotomous variable for 6 types of disorders, using validated grouping software developed by the Agency for Healthcare Research and Quality: 38 adjustment disorders, anxiety disorders, mood disorders, personality disorders, SUDs, and miscellaneous disorders (eg, eating disorders, somatoform disorders). We also summed the number of types of disorders from 0 to 6. We also created a category of MH disorder (any adjustment, anxiety, mood, personality, or miscellaneous MH disorder) comorbid with an SUD.
Opioid Use
Data included all opioid prescriptions (including date, dose, and type of opioid) regardless of indication for opioid use. Buprenorphine was excluded, as the oral formulation is not Food and Drug Administration approved for pain treatment.
For years 2000 and 2005, we formed an analytic file including all individuals with one of our tracer NCPC diagnoses in one of those years. We recorded the total number of opioid prescription fills for each patient within the calendar year and calculated the number of days supplied in the year, as recorded by the dispensing pharmacist.
There is no standard definition of chronic opioid therapy, so we relied on our clinical judgment and the frequency distribution of number of days of opioids used to define chronic opioid therapy as receiving greater than 90 days supply of opioids during the calendar year. This threshold was chosen, because it is unlikely that an individual would receive opioids for more than 90 days (4 prescriptions) for acute conditions. Furthermore, it seems that 90 days represents an important point in the treatment process in which clinicians will want to know the clinical risk of continuing opioid therapy. Finally, in our data of those individuals with more than 90 days of opioid use in one calendar year, approximately 25% go on to >180 days in the following year. Hence, we believe, this is a reasonable ''gateway'' or ''threshold'' time point for trend and risk analyses.
Opioids were categorized into Drug Enforcement Administration (DEA) Schedule II opioids and Schedule III to IV opioids. 39 Schedule II opioids are the most highly regulated and are felt to be most prone to abuse, but abuse of Schedule III hydrocodone products is the most common form of prescription opioid abuse. Total morphine equivalents for each prescription were calculated by multiplying the quantity of each prescription by the strength of the prescription (milligrams of opioid per unit dispensed). The quantity-strength product was then multiplied by conversion factors derived from published sources to estimate the milligrams of morphine equivalent to the opioids dispensed in the prescription. [40] [41] [42] The total average dose in morphine equivalents per day supplied was calculated by summing the morphine equivalents for each prescription filled during the year for each patient and dividing by the number of days supplied. The percentage of the morphine equivalents that were Schedule II opioids was calculated by dividing the Schedule II morphine equivalents dose by the total morphine equivalents dose.
Data Quality Issues
To protect against data entry errors, we treated as an outlier any value for days supply or quantity greater than 2 times the 99th percentile value for the particular opioid. Outliers were then handled as if they were missing data. If either quantity or days supply was missing for a particular prescription, then morphine equivalents were not calculated for that prescription. The estimate of total morphine equivalents was inflated by the total number of prescriptions in the year (including those with missing data) divided by the number of prescriptions with valid data (ie, not counting the ones with missing/outlier data). This approach conservatively estimates the morphine equivalents for prescriptions with missing/outlier data as being equal to the average prescription in the year. In both samples, total missing was less than 1.5%, and outliers were less than 0.5%.
Analysis
We first calculated the percentage of enrollees with a NCPC diagnosis in 2000 and 2005 for each plan. Among enrollees with a NCPC diagnosis, we calculated the percentage with 1, 2, 3, or 4+ unique MH and SUD diagnosis types as per AHRQ categories (adjustment disorder, anxiety disorder, mood disorder, personality disorder, SUD, and miscellaneous) and the percentage with each particular MH or SUD tracer diagnosis. We calculated the percentage of individuals with NCPC who had any prescription opioid use and the percentage who had greater than 90 days supply in the calendar year by number and type of MH or SUDs. We compared the percentage having greater than 90 days supply between patients with and without any MH or SUD disorders using w 2 tests. For those with any opioid use, we calculated the average number of days supplied and average dose per day in morphine equivalents.
We computed the percent change between 2000 and 2005 data for each variable. The 95% confidence intervals for percent change were derived, using the Fieller method. All the analyses were performed, using SAS 9.1 (SAS Institute Inc, Cary, NC). Table 2 shows rates of any use of prescribed opioids and >90 days use of prescribed opioids in a calendar year, among those with NCPC, by MH and SUD categories. In both Arkansas Medicaid and HealthCore, those with a MH or SUD diagnosis were more likely to have any opioid use. Among those with any MH or SUD, those with more diagnoses had higher rates of any opioid use (P<0.0001, for both samples, in both 2000 and 2005). Rates of any opioid use were substantially higher in Arkansas Medicaid than in HealthCore, but rates of any opioid use increased between 2000 and 2005 for almost all groups. Rates of opioid use were especially high in the comorbid MH/SUD category.
RESULTS
Among individuals with NCPC, the proportion of individuals with chronic opioid use (greater than 90 d supply) was higher than among those with an MH or SUD diagnosis than among those without a MH or SUD diagnosis ( Table 2 ). For example, in the 2005 HealthCore data, individuals with a mood disorder diagnosis were 3 times more likely to have greater than 90 days of opioid use compared with those with no mood disorder diagnosis (12% vs. 4%, P<0.001). Chronic opioid use was found in nearly one-third (31%) of Arkansas Medicaid enrollees with a MH or SUD diagnosis in 2005. The rates of chronic opioid use (greater than 90 d) also grew substantially between 2000 and 2005 for enrollees in both health plans with NCPC and any MH or SUD diagnosis (34.9% increase among HealthCore and an increase of 55.4% among Arkansas Medicaid enrollees). Table 3 provides data on days supply and percentage of the total opioid dose that was Schedule II opioids among enrollees with NCPC and any opioid use. In both Arkansas Medicaid and HealthCore individuals with an MH or SUD diagnoses received greater days supply of opioids than individuals without a MH or SUD, and these differences were large and consistent across years. For example, in the 2005 HealthCore population, among those who received any opioids, individuals without a MH or SUD diagnosis received on average 44.0 days of opioids, whereas those with any MH or SUD diagnosis received 89.6 days (P<0.001). In 2005, among Health-Core enrollees with a MH or SUD diagnosis, the average days supply ranged in individuals from 81 days for those with 1 diagnosis to 161 days for those with a comorbid MH/SUD. In the 2005 Arkansas Medicaid population, among those who received any opioids, individuals without a MH or SUD diagnosis received on average 102.6 days of opioids, whereas those with any MH or SUD diagnosis received 136.3 days (P<0.001). The days supplied increased significantly between 2000 and 2005 for all diagnostic groups, but rates of increase were higher among those with any MH or SUD diagnosis in both populations. Table 3 also shows the percentage of the total opioid dose that was Schedule II. Although the large majority of opioid use was non-Schedule II, the percentage of Schedule II opioid use was higher in individuals with MH/SUD diagnoses than in those without an MH/SUD diagnosis. For example, among HealthCore patients with an MH/ SUD in 2005, 17.4% of their total opioid use (both Schedules II and III) was Schedule II; the corresponding Figure 1 in 2005 for HealthCore patients with no MH/SUD was 13.1%. The percentage of Schedule II opioids increased rapidly in all groups between 2000 and 2005. The average daily dose of opioids in milligram morphine equivalents was generally between 50 and 55 mg, and dose did not vary widely between diagnostic subgroups or health plans (data not shown). The average daily dose generally increased (<10%) between 2000 and 2005 in HealthCore and decreased (<10%) in Arkansas Medicaid.
DISCUSSION
Our study of 2 dissimilar clinical populations revealed that chronic opioid use for patients with NCPC was more common and increased more rapidly from 2000 to 2005 among enrollees with MH/SUD diagnoses in both populations. Duration and potency of opioid therapy (percentage of Schedule II opioids) were significantly higher in patients with an MH/SUD diagnosis. As patients with MH/SUD diag-noses have been excluded from most trials of opioid therapy for NCPC, there is no evidence base for these prescribing trends. Treatment guidelines recommend caution in prescribing opioids to patients with SUDs but are generally silent about MH disorders as risk factors for opioid abuse, although they do mention the necessity of assessment and appropriate treatment of MH disorders in this population.
Increasing Rates of MH/SUD Diagnoses in NCPC Patients
Rates of MH/SUD diagnosis among patients with NCPC increased by nearly 50% in both populations during this period. Mood, anxiety, and substance abuse disorders were the most common MH/SUD diagnoses and increased the most from 2000 to 2005. By 2005, over a third of the adult Arkansas Medicaid NCPC patients had a MH/SUD diagnosis. These increased rates of diagnosis may be due to better detection of MH disorders or SUDs in primary care. Although the population prevalence of mental disorders did not increase between 1990 and 2003, the rates of treatment increased significantly. 43 These increasing rates of treatments were most marked in the general medical sector where most chronic pain treatment takes place. 44 These increases in rates of treatment are likely accompanied by increases in rates of diagnosis. In addition, it is believed that direct-to-consumer advertising both increased recognition of the MH symptoms and diminished stigmaassociated MH disease, resulting in higher diagnosis and treatment rates, although this does not explain the increased rate of SUD diagnoses. However, nondetection and under-diagnosis of MH/ SUDs occur commonly, and the true rates of MH/SUDs in the population of patients with NCPC may be higher. Rates of MH and SUD diagnoses in the HealthCore population tended to be lower than estimates from population surveys, 45, 46 whereas in the Arkansas Medicaid sample rates of MH diagnoses were higher than estimates from population surveys, but rates of SUDs tended to be similar.
Opioid Use Higher in Individuals With MH/SUDs
Among individuals with NCPC, those with MH/SUD diagnoses were more likely to receive opioids than those without MH/SUD diagnoses. The differences between NCPC patients with and without MH/SUD diagnosis were even larger when we investigated chronic use (greater than 90 d of opioids). In HealthCore, individuals with NCPC and a MH/SUD diagnosis were nearly 3 times more likely to have more than 90 days of opioid use, compared with enrollees with just NCPC (11% vs. 4%). In Arkansas Medicaid in 2005, fully 31% of eligible individuals with NCPC and a MH/SUD diagnosis received more than 90 days of opioids. Furthermore, the percentage of the total opioid dose that was Schedule II opioids was higher among individuals with MH/SUD disorders than among those without these disorders.
We cannot definitively state why NCPC enrollees with MH/SUDs were more likely to receive opioids than NCPC enrollees without MH/SUDs, and to receive them chronically, but there are a number of potential reasons. First, individuals who have greater use of opioids may have more severe pain with more activity interference, precipitating both their MH diagnosis and opioid use. 47 Second, MH and SUDs may increase pain caused by NCPCs 48 and decrease responsiveness to opioids, 49 requiring greater use of opioids. Third, individuals with MH/SUDs may be using the opioids to ''self-medicate'' their emotional pain and its associated physical symptoms. [50] [51] [52] Fourth, individuals with MH/SUDs may be more likely to seek opioids for misuse than individuals without MH/SUDs. 1 Fifth, most opioids are prescribed in primary care to patients with multiple physical health and MH conditions. 30 In these complex patients, busy clinicians may focus on the physical symptoms, using opioids to provide relief to their patients. Finally, physicians may be more likely to diagnose MH and SUDs in their patients receiving opioids.
The high (and growing) rates of opioid use among individuals with MH/SUDs may have positive or negative implications for their psychiatric treatment. On the one hand, increased use of opioids may mean improved pain control, which would likely facilitate the treatment of associated mood or anxiety disorders. On the other hand, patients with MH/SUDs have often been excluded from randomized opioid trials, so we know less about the balance of benefits and risks of NCPC treatment with opioids in this group. 28 MH/SUD disorders may be risk factors for iatrogenic opioid abuse. 6, 9, 14, 18, 19 Thus, the use of opioids is higher and is growing faster in the population where the benefits of opioids are least established and the vulnerability to iatrogenic addiction is highest. Further, opioids have a low therapeutic index, and individuals with MH/SUD disorders could intentionally or unintentionally overdose on these medications. There is evidence of increasing intentional and unintentional deaths from opioid overdoses. It is unclear what role MH/SUDs are playing in such cases. 53 Finally, prescription opioids might be substituting for or disrupting other appropriate treatment. 54 
Future Directions
Patients with chronic pain and MH or SUDs are more distressed and more complicated to care for than patients who have only chronic pain, and there is much we need to understand to improve their clinical care. For example, we need to better understand the relationship between chronic pain and MH illness, and future studies are needed to disentangle this complex relationship. Furthermore, the optimal treatment for these individuals has not been defined, and future studies should focus on ways of improving care for these patients. For example, in one small study investigating the efficacy of a care management model for comorbid depression and osteoarthritis pain in older primary care adults, patients showed improvements in both their depression and pain. 55 In a collaborative care pain intervention in Veterans Affairs primary care clinics, intervention patients experienced greater improvement in pain and depression severity, compared with patients receiving treatment as usual. 56 
Limitations
Our data are from diverse sources but are not nationally representative, so the generalizability to the larger population is unknown. Arkansas Medicaid serves a low-income, vulnerable population in the South-Central United States. HealthCore has enrollees in many states in the Midwest, West, and Southeast, most of whom are working, middle, or upper class. Our intent in investigating these 2 dissimilar populations was not to draw contrasts but to describe the current range of opioid prescribing practices. Indeed, the much higher burden of disease in Arkansas Medicaid, measured in terms of both rates of NCPC and MH/SUD diagnoses, makes comparisons problematic. Despite differences in the overall burden of disease and socioeconomic status between the 2 populations, broad based increases in NCPC diagnosis, chronic opioid use, days supply, and opioid potency emerged for patients with MH/SUDs in both groups. Although we relied upon conversion factors from published sources to derive morphine equivalents, [38] [39] [40] there are no canonical conversion tables, and estimates of conversion factors differ, generally by small amounts. Differences between conversion tables were resolved by consensus among the clinicians on this study in collaboration with other researchers and clinicians.
Methadone presents 2 challenges for a study, such as ours. First, published estimates of conversion factors for methadone to morphine equivalents differ considerably (more so than conversion factors for other opioids to morphine equivalents). Second, we were not able to separate methadone used for pain from methadone used for methadone maintenance. However, methadone accounted for a relatively small amount of total opioid use in our sample, and methadone maintenance is not common. For example, there is only 1 methadone clinic in all of Arkansas.
We relied on administrative data for diagnoses and for pharmacy records. No independent clinical assessment of patients to confirm diagnoses could be done. Pain diagnoses have high specificity, although sensitivity is likely lower. 57 Our study does not reflect opioids bought over the internet without a prescription 58 or bought illegally. As we analyzed each year's data separately and did not track individual participants' status from year to year, our results represent population trends and not the trends of individual enrollees.
Some MH and substance use diagnoses may be more ''popular'' in different time periods. For example, the number of outpatient physician visits for bipolar disorder increased rapidly for children between 1994 and 2003, which also increased for adults. 59 The possible implications of this for the current study are uncertain, although we would note that the diagnosis rates increased for all MH/ SUDs categories in our study.
CONCLUSIONS
Our results indicate that opioid use for NCPC was more common, more prolonged, more potent, and increased more rapidly from 2000 to 2005 among enrollees with MH and SUD diagnoses in both of these populations. As there is no evidence base for these higher rates of opioid use among individuals with MH and SUDs, clinicians should carefully monitor the use of prescription opioids in their patients with MH and SUDs and determine whether these are substituting for or interfering with other appropriate MH and substance abuse treatment.
